Blueprint Medicines Corp (BPMC)
95.40
+0.61
(+0.64%)
USD |
NASDAQ |
Mar 28, 15:05
Blueprint Medicines Cash from Investing (TTM): 274.04M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 274.04M |
September 30, 2023 | 141.99M |
June 30, 2023 | 19.34M |
March 31, 2023 | 64.34M |
December 31, 2022 | -149.54M |
September 30, 2022 | -443.21M |
June 30, 2022 | -206.90M |
March 31, 2022 | -399.15M |
December 31, 2021 | -225.86M |
September 30, 2021 | 45.56M |
June 30, 2021 | -488.65M |
March 31, 2021 | -361.91M |
December 31, 2020 | -434.25M |
September 30, 2020 | -290.98M |
June 30, 2020 | 213.69M |
March 31, 2020 | -45.92M |
December 31, 2019 | -16.47M |
September 30, 2019 | -27.96M |
June 30, 2019 | -85.91M |
Date | Value |
---|---|
March 31, 2019 | 147.35M |
December 31, 2018 | -161.09M |
September 30, 2018 | -167.46M |
June 30, 2018 | -191.92M |
March 31, 2018 | -327.26M |
December 31, 2017 | -72.35M |
September 30, 2017 | -260.51M |
June 30, 2017 | -268.25M |
March 31, 2017 | -112.67M |
December 31, 2016 | -218.82M |
September 30, 2016 | -84.22M |
June 30, 2016 | -69.42M |
March 31, 2016 | -75.16M |
December 31, 2015 | -6.079M |
September 30, 2015 | -2.794M |
June 30, 2015 | -2.161M |
March 31, 2015 | -1.891M |
December 31, 2014 | -0.70M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-488.65M
Minimum
Jun 2021
274.04M
Maximum
Dec 2023
-113.52M
Average
-65.91M
Median
Cash from Investing (TTM) Benchmarks
Apellis Pharmaceuticals Inc | -0.674M |
Alnylam Pharmaceuticals Inc | -336.35M |
Madrigal Pharmaceuticals Inc | -502.52M |
Ionis Pharmaceuticals Inc | -214.13M |
Sarepta Therapeutics Inc | -165.80M |